Identifying a subset of patients with DCIS who have a low likelihood of residual disease at surgical excision following a core needle biopsy

Abstract

Although our multivariable analysis performed well, its clinical utility would be limited as we were unable to identify a subset of patients with DCIS in whom the probability of finding no residual disease is low enough to consider routine use of non-surgical management.

HER2 status might be independent determinant associated with no residual disease at surgical resection in patients with DCIS

“…I want to congratulate Murphy and colleagues for their article in which they tried to investigate a subset of patients with DCIS who have a low likelihood of residual disease at surgical excision following a core needle biopsy. Many variables were included into analysis.…”

Response to HER2 status might be independent determinant associated with no residual disease at surgical resection in patients with DCIS

“…We appreciate the interest Dr Altundag has in our article and the discussion of the importance of human epidermal growth factor (HER2) positivity in patients with Ductal Carcinoma in Situ (DCIS) . As Dr Altundag mentioned, HER2 status was not evaluated in our study, as HER2 testing is not standard practice for DCIS outside of a clinical trial.…”